Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
ASP
MARCH 2024
Bendamustine Q2 2024
Report
Aria analytics
Aria is dedicated to enhancing value for our members through cutting-edge analytics and business intelligence solutions. With this objective, our team has compiled a report to assist members in understanding the product landscape, visualizing ASP trends, and anticipating future ASPs for key products.
Our goal is to empower members with clear insights, enabling well-informed purchasing decisions and the development of sustainable, long-term strategies.
The
© 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
Copyright
no
warranties regarding, the content, accuracy
completeness of the
the
property rights to any pharmaceutical product
content provided in this material is for informational purposes only and is not intended as legal advice or to replace a medical provider’s judgment. All information used in this material has been sourced from publicly available sources. Aria GPO “Aria” does not endorse or approve, assumes no responsibility for, and makes
representations nor
or
information presented. Aria GPO does not own
intellectual
mentioned herein.
Table of contents
• Product comparison
• Average Sales Prices Q1 2024 & Q2 2024
• Reimbursement information for Q2 2024
• Historical ASPs
• Average Change of ASP
• WAC vs. Initial ASPs
• ASP Percent Change from WAC
• Aria ASP predictive model
The content provided in this material is for informational purposes only and is not intended as legal advice or to replace a medical provider’s judgment. All information used in this material has been sourced from publicly available sources. Aria GPO “Aria” does not endorse or approve, assumes no responsibility for, and makes no representations nor warranties regarding, the content, accuracy or completeness of the information presented. Aria GPO does not own the intellectual property rights to any pharmaceutical product mentioned herein.
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
Product comparison
Product Strength & Dosage Treatment
Treanda1 (Cephalon)
Bendeka2 (Teva)
Belrapzo3 (Eagle)
Vivimusta4 (Azurity)
Bendamustine
Hydrochloride5 (Baxter)
Bendamustine
Hydrochloride6 (Apotex)
Injection: 1 vial, Single-Dose ready-to dilute solution
Injection: 1 vial, Single-Dose lyophilized powder ready for reconstitution
Injection, Solution: 1 Vial, Multi-Dose in 1 Carton / 4 Ml in 1 Vial, Multi-Dose
Chronic Lymphocytic
Leukemia, Non-Hodgkin Lymphoma
Cold Chain
Yes
Injection: 1 Vial, Multi-Dose in 1 Carton / 1 Injection in 1 Vial, Multi-Dose
Injection: 1 Vial, Multi-Dose in 1 Carton / 4 Ml in 1 Vial, Multi-Dose
Injection: 1 Vial, Multi-Dose in 1 Carton / 1 Injection in 1 Vial, Multi-Dose
Injection, Solution: 1 Vial, Multi-Dose in 1 Carton / 5 Ml in 1 Vial, Multi-Dose
1.Https://dailymed.Nlm.Nih.Gov dailymed druginfo.Cfm?Setid=39d53698-57fa-7c99-fc5b-f52a55684826
2.Https://dailymed.Nlm.Nih.Gov dailymed druginfo.Cfm?Setid=ace9a43b-f9bd-4896-abfe-0ef4fec67ddf
3.Https://dailymed.Nlm.Nih.Gov dailymed druginfo.Cfm?Setid=9759a4ae-82ca-40cf-9c02-e1cadb21cbdc
4. Https://dailymed.Nlm.Nih.Gov dailymed druginfo.Cfm?Setid=cbcc6eb7-aa62-4599-af49-05203fedb4bb
5. Https://dailymed.Nlm.Nih.Gov dailymed druginfo.Cfm?Setid=766b73e2-49bb-47f9-bbb1-44cfa1a3197e
6.Https://dailymed.Nlm.Nih.Gov/dailymed/druginfo.Cfm?Setid=085dd54c-4212-d879-afef-ee52732a48c0
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
Average Sales Prices Q1 2024 & Q2 2024
ASP Change
*The most recent ASP pricing file from CMS does not contain an entry for Vivimusta
Treanda (Cephalon) Bendeka (Teva) Belrapzo (Eagle) Vivimusta (Azurity) Bendamustine
Bendamustine
Hydrochloride (Baxter)
Hydrochloride (Apotex)
Previous ASP New ASP
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
Product WAC Previous ASP New ASP % Change Avg % Change Treanda (Cephalon) $2,971.80 $867.08 $788.30 -9.08% -5.61% Bendeka (Teva) $2,473.80 $1,392.08 $1,304.81 -6.27% -2.42% Belrapzo (Eagle) $2,597.49 $1,234.81 $837.26 -32.19% -4.35% Vivimusta (Azurity)* $3,209.54 $3,155.94 N/A N/A 0.19% Bendamustine Hydrochloride (Baxter) $2,340.00 $1,960.19 $2,276.79 16.15% 0.84% Bendamustine Hydrochloride (Apotex) $3,209.54 $1,960.19 $2,276.79 16.15% -10.50% -9.08% -6.27% -32.19% 16.15% 16.15% $0 $500 $1,000 $1,500 $2,000 $2,500 $3,000 $3,500
Reimbursement information for Q2 2024
*All reimbursements include Medicare sequestration
**The most recent ASP pricing file from CMS does not contain an entry for Vivimusta
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
Product Launch Date HCPC Code WAC ASP 6% of ASP Anticipated Medicare Reimbursement* Brand Treanda (Cephalon) 1/31/10 J9033 $2,971.80 $788.30 $47.30 $822.23 Bendeka (Teva) 1/31/16 J9034 $2,473.80 $1,304.81 $78.29 $1,360.97 505(B)(2) Belrapzo (Eagle) 5/31/19 J9036 $2,597.49 $837.26 $50.24 $873.30 Vivimusta (Azurity)** 12/31/22 J9056 $3,273.73 N/A N/A N/A Bendamustine Hydrochloride (Baxter) 2/28/23 J9059 $2,340.00 $2,276.79 $136.61 $2,374.79 Bendamustine Hydrochloride (Apotex) 5/31/23 J9058 $3,209.54 $2,276.79 $136.61 $2,374.79
Historical ASPs
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
$0 $500 $1,000 $1,500 $2,000 $2,500 $3,000 $3,500 Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024
Treanda (Cephalon) Bendeka (Teva) Belrapzo (Eagle) Vivimusta (Azurity) Bendamustine Hydrochloride (Baxter) Bendamustine Hydrochloride (Apotex)
Average Change of ASP
This graph showcases the cumulative average change in the average sales price (ASP) for the Bendamustine family, tracking changes from the launch of biosimilars to each quarter's ASP. It highlights the evolution of ASP over the product's lifecycle and the fluctuating rate of change, providing a concise overview of pricing dynamics.
© 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
Copyright
-40% -35% -30% -25% -20% -15% -10% -5% 0% 5% 10% Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024
Treanda (Cephalon) Bendeka (Teva) Belrapzo (Eagle)
Vivimusta (Azurity) Bendamustine Hydrochloride (Baxter)
Bendamustine Hydrochloride (Apotex)
WAC* vs. Initial ASPs
*Refers to the WAC when the first ASP was released
© 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
Copyright
-2.45% -9.66% -14.68% -3.97% -3.41% -2.83% -2.26% -10.55% -11.54% -4.38% -6.75% -38.93% -2.71% -10.21% -13.29% -3.60% -16.23% -29.06% $0 $500 $1,000 $1,500 $2,000 $2,500 $3,000 $3,500
Treanda (Cephalon)
Bendeka (Teva)
Belrapzo (Eagle)
Vivimusta (Azurity)
Bendamustine Hydrochloride (Baxter)
Bendamustine Hydrochloride (Apotex)
WAC First ASP Second ASP Third ASP
ASP Percent Change from WAC*
Treanda (Cephalon)
Bendeka (Teva)
Belrapzo (Eagle)
Vivimusta (Azurity)
Bendamustine Hydrochloride (Baxter)
Bendamustine Hydrochloride (Apotex)
*Refers to the WAC when the first ASP was released
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
-80% -70% -60% -50% -40% -30% -20% -10% 0% Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024
Aria ASP Predictive model
In line with Aria's goal to provide key insights to our members, our analytics team has developed a proprietary predictive ASP model for the Bendamustine product family.
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
$0 $500 $1,000 $1,500 $2,000 $2,500 $3,000 $3,500 Q12019 Q22019 Q32019 Q42019 Q12020 Q22020 Q32020 Q42020 Q12021 Q22021 Q32021 Q42021 Q12022 Q22022 Q32022 Q42022 Q12023 Q22023 Q32023 Q42023 Q12024 Q22024 Q32024Predicted
Treanda (Cephalon) Bendeka (Teva) Belrapzo (Eagle) Vivimusta (Azurity) Bendamustine Hydrochloride (Baxter) Bendamustine Hydrochloride (Apotex)
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential. Thank you. www.ariagpo.com info@ariagpo.com